Literature DB >> 7751707

Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease.

H R Chakkalath1, C M Theodos, J S Markowitz, M J Grusby, L H Glimcher, R G Titus.   

Abstract

Class II major histocompatibility complex (MHC)-deficient (H-2b) mice do not express I-A or I-E molecules and, as a result, do not develop CD4 cells. Thus, they represent the ideal model for examining the importance of CD4 cells and MHC class II molecules in resistance to infection with Leishmania major and the capacity of MHC class I-restricted T cells to mediate resistance to L. major. Class II MHC-deficient mice and control (C57BL/6, normal and nude) mice were infected with L. major. Although MHC class II-deficient mice were able to control infection more effectively than nude mice, cutaneous lesions on the mice eventually progressed, and parasite replication became uncontrolled. These results suggest that CD4 cells and MHC class II molecules are essential for resistance to L. major and that in the absence of these cells and molecules, such mice can transiently control infection with L. major but are unable to resolve such infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751707     DOI: 10.1093/infdis/171.5.1302

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major.

Authors:  H R Chakkalath; A A Siddiqui; A H Shankar; D E Dobson; S M Beverley; R G Titus
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

3.  Assessing the binding of four Plasmodium falciparum T helper cell epitopes to HLA-DQ and induction of T-cell responses in HLA-DQ transgenic mice.

Authors:  N Pimtanothai; M Parra; A H Johnson; C S David; C Katovich Hurley
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Profiles of healing and nonhealing Cryptosporidium parvum infection in C57BL/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection.

Authors:  C M Theodos; K L Sullivan; J K Griffiths; S Tzipori
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

5.  Immunomodulatory effects of the Lutzomyia longipalpis salivary gland protein maxadilan on mouse macrophages.

Authors:  Tess M Brodie; Matthew C Smith; Robin V Morris; Richard G Titus
Journal:  Infect Immun       Date:  2007-03-05       Impact factor: 3.441

6.  Protective response to Leishmania major in BALB/c mice requires antigen processing in the absence of DM.

Authors:  Tirumalai Kamala; Navreet K Nanda
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

7.  CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with histoplasma capsulatum.

Authors:  P Zhou; R A Seder
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  T helper subset differentiation in the absence of invariant chain.

Authors:  D R Brown; K Swier; N H Moskowitz; M F Naujokas; R M Locksley; S L Reiner
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

9.  Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity.

Authors:  Ines Matos; Olga Mizenina; Ashira Lubkin; Ralph M Steinman; Juliana Idoyaga
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

10.  MHC class II expression restricted to CD8alpha+ and CD11b+ dendritic cells is sufficient for control of Leishmania major.

Authors:  Maria P Lemos; Fatima Esquivel; Phillip Scott; Terri M Laufer
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.